Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Results from the IMpassion130 trial for triple-negative breast cancer

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.10.18
Views: 829

Prof Peter Schmid - St Bartholomew Hospital London, UK

Prof Peter Schmid presents data at the ESMO 2018 congress in Munich from the IMpassion130 trial.

This was a global, randomised, double-blind, phase 3 study of atezolizumab nab-paclitaxel vs placebo nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.

For more on these findings, watch his interview with ecancer here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation